novo nordisk glp 1 drug Novo, Lilly buoyed by fast-growing GLP-1 sales Novo Nordisk, Hims & Hers
Description
In the SOUL trial, oral semaglutide showed a 14% MACE reduction (HR 0.86, 95% CI 0.770.96) [22]
Because tirzepatide also acts on the GLP-1 pathway, it slows gastric emptying in much the same way, so the gut side effects tend to look familiar
In 2025, Eli Lilly announced a $27 billion U.S
We invite you to discuss the potential of GLP-1 medications and explore how they can be integrated into your personalized diabetes management plan
No standardised dosing guidance is provided
